Targeted modification | Stages | Enzyme Reaction | Antibody | Final structure | Yield % |
---|---|---|---|---|---|
Agalactosylation | 1 | 3 units/μL β(1,4) galactosidase, 3 units/μL neuraminidase at pH 6.6 | EG2 | FG0 | 85 |
Cetux | FG0 | 94 | |||
IL8 | FG0 | 83 | |||
Polyclonal | FG0 | 62 | |||
Galactosylation | 1 | 2 milli-units/μL β(1,4) galactosyltransferase, 3 mM UDP-galactose, 10 mM MnCl2, 3 units/μL neuraminidase at pH7.5 | EG2 | FG2 | 96 |
Cetux | FG2 | 95 | |||
IL8 | FG2 | 95 | |||
serum | FG2 | 96 | |||
Trimannose (FM3 + FA1) | 2 | Stage 1: 3 units/μL β(1,4) galactosidase, 3 units/μL neuraminidase at pH6.6 Stage 2: 20 units of β-N-acetylglucosaminidase at pH6.6 | EG2 | FM3 | 80 |
FA1 | 11 | ||||
Cetux | FM3 | 78 | |||
FA1 | 15 | ||||
IL8 | FM3 | 76 | |||
FA1 | 18 | ||||
Sialylation (FS1 + FS2) | 2 | Stage 1: 2 milli-units/μL β(1,4) galactosyltransferase, 3 mM UDP-galactose, 10 mM MnCl2 at pH7.5 Stage 2: 100 μg/mL α(2,6) sialyltransferase, 3 mM CMP-Neu5Ac at pH7.5 | EG2 | FS2 | 76 |
FS1 | 16 | ||||
IL8 | FS2 | 37 | |||
FS1 | 38 | ||||
Polyclonal | FS2 | 43 | |||
FS1 | 46 |